Inhibrx Biosciences Inc. (INBX)
$87.08-3.81%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.3B
- Beta
- 3.82
- P/E (TTM)
- -9.81
- Short % float
- 31.59%
- Days to cover
- 11.8
- SI change
- +1.1%
- 1W
- -6.78%
- 1M
- -21.17%
- vs SPY 1W
- -6.64%
- vs SPY 1M
- -23.68%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 4
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-89.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-9.81
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-25.76
P/FCF-
EV/EBITDA-9.54
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO5.07
ND/EBITDA-
BETA3.82
Company news
FAQ
- What is LOPJLB’s current signal on INBX?
- LOPJLB’s latest quantitative signal on Inhibrx Biosciences Inc. (INBX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is INBX in?
- Inhibrx Biosciences Inc. (INBX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Inhibrx Biosciences Inc. (INBX) do?
- Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric wa…